RECURSION PHARMACEUTICALS

Recursion Pharmaceuticals gives directors free stock to align interests, boosting governance and innovation in AI‑driven biotech while navigating market swings.

Recursion Pharmaceuticals awards 3 million restricted‑stock units to 24 new hires, boosting talent retention while driving AI‑powered drug discovery in oncology, rare diseases, neuroscience and more.

Recursion Pharmaceuticals sells 200k shares as insider Gibson divests amid a $3.72 stock price and negative P/E, highlighting investor uncertainty and a tech‑driven biotech pivot.